Martin Simonetti, CEOUnder the leadership of CEO Martin Simonetti, the company operates with a guiding principle: start with the end in mind. This philosophy informs every aspect of PBS Biotech’s work, from product design to client partnerships and global strategy.
Simonetti explains, “Most of these programs don’t fail because of biology; they generally stall during scale-up. So, we’ve developed products that provide continuity from early research through GMP and help get therapies to patients faster. We always think about the end when we’re starting something, and it gives us a very different view of what we’re trying to achieve.”
This approach underscores PBS Biotech’s commitment to removing the bottlenecks that often hinder cell therapy commercialization.
Innovation with Purpose
Traditional stirred-tank bioreactors were designed for cells that produce a product, not for processes in which the cells themselves are the therapeutic agent. Recognizing this gap, PBS Biotech developed the Vertical-Wheel® platform, a system purpose-built for sensitive and heterogeneous cell types. It combines gentle, low-shear mixing with precise control over hydrodynamic conditions, ensuring cell viability and uniformity across scales.
We always think about the end when we're starting something, and it gives you a very different view of what you're trying to achieve.
Addressing the Allogeneic Therapy Bottleneck
As the cell therapy field matures, allogeneic therapies are moving toward commercialization. Yet biological success alone does not guarantee a viable product. Manufacturing economics, process consistency, and operational readiness remain critical hurdles. PBS Biotech addresses these challenges by integrating process development services with its hardware, offering what it calls “Success Bundles.”
From media optimization to operational design, the company works closely with clients to ensure that early decisions do not become late-stage liabilities. By embedding regulatory and manufacturing considerations from the outset, PBS Biotech creates a predictable path to commercialization. This integration of technology and services sets the company apart from traditional equipment providers, which often disengage after delivery.
Ensuring Consistency and Reproducibility
Process consistency is a cornerstone of PBS Biotech’s platform. The company’s quality systems, embedded across both equipment and services, ensure that scaling does not compromise cell quality. The Vertical-Wheel® platform creates a controlled hydrodynamic environment that maintains reproducibility from small research volumes to large production scales.
A case in point is pluripotent stem cell expansion, where uniform aggregate formation is critical. Minor variations in conventional systems can lead to inconsistent outcomes, affecting downstream differentiation and yield. The Vertical-Wheel® platform minimizes this variability, establishing a framework that is both repeatable and adaptable across multiple cell types. Clients can confidently transition across different modalities while maintaining a robust manufacturing foundation.
The Bridge Between Biology and Manufacturing
PBS Biotech’s bioprocess R&D team plays a central role in translating innovation into operational reality. Acting as a bridge between biology and manufacturing, the team collaborates with clients to ensure that processes are clinically relevant, scalable, and economically viable.
Simonetti emphasizes the importance of this collaboration: “Manufacturing reality is just as important as scientific promise. We ensure clients can go from the smallest scale—our Mini—to our largest 80-liter system, giving them all the tools in between to do so economically, reliably, and consistently.”
By focusing on de-risking early-stage processes and scaling innovations that meet reproducibility, GMP, and customer requirements, PBS Biotech accelerates clinical translation and minimizes operational setbacks.
The Competitive Advantage of Integration
What sets PBS Biotech apart is its integrated model, which combines equipment manufacturing with contract process development which has resulted in an NPS score of 80, putting PBS in the top 5 percent of all companies. Most suppliers provide tools and disengage; PBS Biotech remains an active partner throughout the client’s journey. This model reduces scale-up risk, accelerates timelines, and allows clients to benefit from the company’s deep process expertise.
-
We ensure clients can go from the smallest scale, our mini, to our largest 80-liter system, giving them all the tools in between to do it economically, reliably, and consistently.
By offering both hardware and hands-on support, PBS Biotech provides more than a product—it delivers a partnership. This approach ensures that therapies advance efficiently from discovery to production while maintaining quality, reproducibility, and compliance.
Global Expansion and Quality Assurance
Global growth has been a key priority for PBS Biotech, particularly following its 2023 funding round. Investments have focused on product innovation, customer success infrastructure, and international expansion. The company now has a presence in Europe and Asia, providing clients worldwide with access to technical support and field application expertise.
ISO 9001 certification and adherence to rigorous quality systems underpin this expansion. Simonetti notes, “ISO certification signals discipline, transparency, and operational rigor in a highly regulated environment. Consistency and documentation matter as much as innovation, and our clients depend on our quality systems to build trust—not just with us, but with regulators.”
By combining these certifications with robust process development services, PBS Biotech enables clients to navigate regulatory landscapes confidently across geographies.
Preparing for the Future of Cell Therapy
Today, PBS Biotech anticipates industry-wide shifts toward standardization, automation, and scalable manufacturing. Platforms that combine biological performance with operational predictability and cost efficiency will define the next era of cell therapy. PBS Biotech is positioning itself as a leader in this transition, with technologies like MiniPRO™ enabling high-throughput process development in a parallel closed system that mirrors clinical manufacturing.
The company’s long-term goal is to make the Vertical-Wheel® platform the industry standard for allogeneic cell therapy manufacturing.
Simonetti articulates this vision clearly: “PBS is evolving from a technology innovator into a long-term success partner for cell therapy companies. Innovation matters, but execution will define our outcomes. We’re building bridges across scale-up chasms, combining our technology with execution, and continuing to innovate. Ultimately, we believe these capabilities position us to help define the future of cell therapy manufacturing.”
A Partner from Research to Patients
The success of PBS Biotech is measured not only by technological innovation but also by its impact on real-world clinical translation. The company’s collaborations have helped clients advance therapies through late-stage clinical trials, providing the expertise and tools needed to scale processes from bench to bedside. By embedding quality systems, reproducible workflows, and process development support within its platform, PBS Biotech ensures that clients can maintain consistency and operational feasibility at every stage.
With a philosophy rooted in foresight and collaboration, PBS Biotech is more than an equipment provider—it is a partner in the journey from scientific discovery to therapeutic delivery. Its integrated approach, coupled with ISO-certified quality systems and a global support network, positions the company as a trusted enabler of cell therapy commercialization.
Defining the Future
PBS Biotech has successfully aligned innovation with execution, ensuring that therapies reach patients faster and more reliably. Its Vertical-Wheel® platform addresses critical gaps in traditional bioreactor systems, while Success Bundles and process development services provide clients with a comprehensive solution for scale-up and GMP manufacturing.
Under Simonetti’s leadership, the company continues to anticipate challenges before they arise, delivering technology and expertise that reduce operational risk and accelerate timelines. By combining predictive hardware, rigorous quality systems, and hands-on support, PBS Biotech is defining the standard for cell therapy manufacturing, ensuring that the promise of cellular therapies translates into tangible patient outcomes.
Through foresight, precision, and a commitment to collaboration, PBS Biotech demonstrates that the journey from research to patients is not just a vision—it is a replicable, scalable, and efficient reality. The company’s work ensures that the next generation of cell therapies can move from concept to clinic with confidence, efficiency, and reproducibility, establishing PBS Biotech as a long-term partner and leader in the global cell therapy ecosystem.
Scaling Cell Therapy from Research to Reliable Manufacturing
Cell therapy development has moved beyond proof-of-concept science into the demands of repeatable manufacturing and clinical delivery. For executives responsible for advancing these programs, the challenge no longer sits solely in demonstrating biological efficacy but in ensuring that therapies can be produced consistently, economically and at scale without introducing new risks at each stage of growth. Many programs falter not because the underlying biology fails, but because the transition from laboratory processes to production environments introduces variability, cost escalation and regulatory friction that were not addressed early enough.
A central tension defines decision-making in this space: early-stage flexibility often conflicts with downstream manufacturability. Processes designed for discovery rarely translate cleanly into compliant, large-scale production systems, forcing costly redesigns and delays. The ability to maintain continuity from early research through clinical and commercial manufacturing becomes a defining advantage. Organizations that anchor development decisions to the end-state requirements tend to avoid re-engineering cycles and preserve both timelines and capital efficiency.
"The right technology and development support help transform promising cell therapies into scalable, commercially viable treatments."
Technology architecture plays a decisive role in this continuity. Conventional bioreactor systems were originally engineered for scenarios where cells produce a therapeutic output rather than being the therapeutic product themselves. This distinction has profound implications. Sensitive, heterogeneous cell populations require controlled environments that preserve viability while enabling uniform growth across scales. Systems that introduce shear stress or inconsistent mixing conditions can compromise both quality and reproducibility, particularly as volumes increase. A platform that maintains predictable hydrodynamic conditions across different scales reduces the risk of variability and supports smoother progression from bench to manufacturing.
Process design and execution must evolve in parallel with technology. Early development decisions often carry hidden consequences that surface only in late-stage production or regulatory review. Building processes that are inherently scalable, supported by structured quality systems and aligned with regulatory expectations helps prevent these downstream liabilities. Consistency is not achieved through isolated optimization efforts but through disciplined integration of equipment, process knowledge and quality oversight from the outset. This approach ensures that reproducibility is embedded rather than retrofitted, while also improving audit readiness and documentation integrity across programs.
"Strong manufacturing processes help turn promising cell therapies into reliable treatments that can reach more patients efficiently and consistently."
Economic viability remains another defining pressure. As allogeneic therapies move toward commercialization, predictable cost structures become as important as scientific validation. Manufacturing processes must deliver repeatability without excessive resource consumption, while maintaining compliance with increasingly stringent regulatory frameworks. The ability to align process design with cost control and operational readiness determines whether promising therapies can reach patients at scale.
PBS Biotech stands out as a partner that addresses these interconnected challenges through an integrated platform and development model. It designs its vertical wheel bioreactor technology specifically for cell-based products, enabling gentle, uniform mixing that protects cell integrity while supporting scalability. By allowing users to operate on a single platform from early research through GMP production, it reduces the need for process re-engineering and preserves continuity across development stages. Its combined offering of equipment and process development services extends beyond tool delivery, providing direct support in media optimization, scale translation and process design to ensure early decisions remain viable in later stages. This integrated approach positions it as a long-term partner capable of guiding therapies from concept to clinical and commercial realization.
...Read more
Cell Therapy Product Development Info
Q1
What Does Cell Therapy Product Development Involve?
Cell Therapy Product Development turns promising living-cell science into a controlled, scalable process that can support research, clinical translation and future manufacturing. It includes selecting a culture platform, defining process parameters, protecting cell quality, improving yield and building a path from early experiments to larger production runs. Because cells are sensitive to shear, nutrients, oxygen and handling conditions, development work must balance biological performance with repeatability. The goal is not only growth in a vessel, but a process that can be studied, adjusted and transferred with confidence.
Q2
How Does PBS Biotech Support Cell Therapy Product Development?
PBS Biotech supports Cell Therapy Product Development through single-use bioreactor systems and process development services designed for cell-based therapies. Its Vertical-Wheel technology is built for scalable, low-shear mixing, helping researchers move from small-scale testing toward clinical-stage and commercial-scale production. The company’s platform spans 0.1L to 80L, giving teams a connected route for optimization, scale-up and manufacturing preparation without changing the core mixing approach.
Q3
Why Do Bioreactor Design and Scale-Up Matter?
Bioreactor design is central because living-cell products often depend on consistent culture conditions. Cell Therapy Product Development benefits when small-scale studies can reflect how a process may behave at larger volumes. Low-shear mixing, controlled oxygen transfer, temperature stability and efficient media exchange all influence cell expansion and final product quality. A scale-up strategy also helps reduce late-stage process changes that can slow translation, complicate comparability or add avoidable cost before a therapy reaches clinical production.
Q4
What Capabilities Should Buyers Look For in Cell Therapy Product Development?
Organizations evaluating Cell Therapy Product Development should look for process control, repeatable performance, closed-system options, scalability and support across relevant cell types. Useful platforms should help teams monitor critical conditions and compare results across multiple cultures. Documentation, application resources, training and service support also matter because product development is rarely a one-step activity; it requires methodical adjustment as biology, yield goals and manufacturing expectations evolve. Strong support can help teams interpret process behavior rather than simply operate equipment.
Q5
How Does PBS Biotech’s MiniPRO Fit Into Development Workflows?
PBS Biotech’s MiniPRO brings Cell Therapy Product Development into a high-throughput, small-scale format. The multi-parallel Vertical-Wheel bioreactor platform can run up to 24 independent cultures in an automated closed system, with real-time control and monitoring for temperature, agitation, oxygenation and pH. It also supports perfusion media exchange, giving teams a way to test conditions efficiently before committing to larger-scale bioreactor runs.
Q6
How Can Better Development Platforms Improve Cell Therapy Manufacturing Readiness?
Better platforms make Cell Therapy Product Development more practical by connecting early research decisions with future manufacturing needs. When process teams can compare variables, preserve cell quality and scale with confidence, they are better positioned to manage cost, consistency and risk. This is especially important for advanced therapies that rely on reliable expansion of cells such as pluripotent stem cells, mesenchymal stem cells, T cells and NK cells for both development learning and downstream planning as workflows mature.
